This article is aimed to provide readers with an updated review on the applicability, efficacy, and challenges of employing donor apoptotic cell-based therapies to promote transplantation tolerance in various experimental and clinical settings.
INTRODUCTION
Apoptosis (programmed cell death) of senescent or injured cells occurs on a daily basis during normal development, tissue-repair, and diverse pathologic conditions. Release of intracellular contents of dying cells into local milieu triggers inflammatory responses, therefore, it is necessary for apoptotic debris to be promptly cleared by tissue-resident macrophages and dendritic cells to avoid inflammation. This process is called efferocytosis [1 & ]. Cells undergoing apoptosis express several 'find me' and 'eat me' signals. Diverse receptors on phagocytes sense these signals, facilitating recognition and engulfment of apoptotic bodies [2, 3] . Furthermore, engagement of these receptors stimulates SOCS1/3 signaling in phagocytes, which in turn suppresses Toll-like receptor and NFkB signaling, resulting in the inhibition of inflammatory cytokines [4] . Efferocytosis further stimulates macrophages and dendritic cells to express anti-inflammatory cytokines (IL-10 and TGF-b1) and restrains their activation [5] [6] [7] [8] [9] . Therefore, efferocytosis is an active biochemical process that exerts a profound impact on innate and adaptive immunity. Consequently, impaired or delayed clearance of apoptotic cells results in activation of both antigen-presenting cells (APCs) and T cells [10] . For example, genetic deficiency of the Mer receptor tyrosine kinase, a phagocytic receptor facilitating efferocytosis, leads to delayed clearance of apoptotic cells and lupus-like autoimmunity in mice [2, 11] . Similarly, impaired identification and clearance of apoptotic cells in humans have also been reported in systemic lupus erythematosus patients [12] [13] [14] . Thus, efficient removal of apoptotic cells by macrophages and dendritic cells are critical for tissue homoeostasis and maintenance of self-tolerance.
Organ transplantation is often the only curative treatment for patients with end-stage organ diseases. Despite significant advances in new immunosuppressive drugs, chronic rejection is still common and side effects of life-long immunosuppression are inevitable [15] . Therefore, induction of donor-specific tolerance has been the 'holy grail' in transplantation that could potentially obviate these complications. The profound immunomodulatory effects of apoptotic cells on immunity have motivated several laboratories to investigate the potential of donor apoptotic cells in promoting transplantation tolerance. Intravenous infusions of donor apoptotic dendritic cells or recipient dendritic cells loaded with donor apoptotic cells provide protection to murine cardiac allografts [16, 17] . Similarly, infusions of donor apoptotic cells generated by g or ultraviolet B (UVB) irradiation have been shown to promote bone marrow engraftment without graft-versus-host disease (GVHD) in allogeneic BMT [18] . Our laboratory has demonstrated that donor splenocytes pretreated with a chemical cross-linker ethylenecarbodiimide (ECDI) rapidly undergo apoptosis, and that infusions of such apoptotic donor splenocytes (ECDI-SP) effectively induce donor-specific tolerance in various mouse models of allogeneic and xenogeneic transplantation [19] [20] [21] [22] [23] . These data collectively highlight the potential of using donor apoptotic cell-based therapies for inducing robust donor-specific tolerance for clinical applications.
In this review, we will discuss the efficacy of this approach in various transplant scenarios and potential obstacles for its successful implementation in clinically relevant settings.
ORGAN-SPECIFIC HETEROGENEITY IN TRANSPLANTATION TOLERANCE BY DONOR APOPTOTIC CELLS
Different organs display varying propensities for tolerance [24] . Using a mouse model of pancreatic islet transplantation, we have previously shown that peri-transplant intravenous infusions of donor ECDI-SP induce robust donor-specific tolerance to the allogeneic islets. In this setting, APCs play a crucial role in establishing and maintaining tolerance posttransplantation [25] . We and others have shown that efferocytosis by recipient APCs is critical in engaging several parallel tolerance mechanisms, including induction of Foxp3 þ regulatory T cells (Tregs), anergy and depletion of allo-reactive T cells, and programmed-death (PD)-1/PD-ligand 1 signaling. In concert, these mechanisms promote indefinite survival of the transplanted allogeneic islets [19, 21, 26] .
In contrast to allogeneic islet transplantation where infusion of donor ECDI-SP provides indefinite protection [19, 27] , the same tolerance regimen is less efficacious in allogeneic heart transplantation in providing long-term graft protection, but instead requires the addition of a short course of rapamycin [20] . Such a difference in tolerance efficacy by donor ECDI-SP may be attributed to the difference in allogeneic endothelial targets present in the allogeneic heart, but not in islets. Interestingly, even among solid organs (lung versus heart), efficacy of tolerance varies dramatically [28,29 & ]. In full-mismatched miniature swine cardiac and lung transplant models, Sommer et al. [29 & ] show that a tolerance protocol constituted of nonmyeloablative irradiation with donor-specific transfusion (DST) and immunosuppression, while providing prolonged protection to the lung allografts, fails to promote heart allograft survival. Such organ-specific heterogeneity has also been observed in other nonapoptotic cell-based tolerance regimens [28] . For example, Madariaga et al. [28] demonstrate that tacrolimus induces tolerance to lung allografts, whereas cardiac allografts are readily rejected unless they are co-transplanted with the same donor kidney, suggesting the tolerogeneicity of kidneys possibly owing to Treg induction by kidney tubular epithelial cells. These data thus underscore the need for a better understanding of organ-specific factors underlying tolerance susceptibility for the design of apoptotic cell-based organspecific tolerance protocols.
In allogeneic BMT, donor T cells co-infused with the hematopoietic stem cells readily proliferate and differentiate in response to host APCs and initiate GVHD [30] , resulting in high morbidity and mortality [31] . Employing a mouse model of allogeneic
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BMT, Bittencourt et al. [18] report that infusion of apoptotic cells of either donor or recipient origin effectively promotes donor bone marrow engraftment without GVHD. In a mouse model of lethal GVHD, extracorporeal photopheresis that induces autologous apoptotic cells has also been shown to promote recipient survival without GVHD [32] . In these studies, bone marrow engraftment and improvement of GVHD following apoptotic cells infusions were mediated by TGF-b modulating several cell populations, including conventional dendritic cells, plasmacytoid dendritic cells, natural killer cells, and Tregs [32] [33] [34] [35] . These findings are highly clinically relevant as allogeneic BMT is now being used to promote transplantation tolerance for solid organs [36, 37] . Recently, a phase I/IIa multicenter clinical trial evaluated the safety, tolerability, and efficacy of apoptotic cell administration in 13 patients undergoing human leukocyte antigenmatched allogeneic BMT [38] . The study demonstrated safety and tolerability of a single infusion of donor apoptotic cells in these recipients, as well as a potential efficacy in reducing acute GVHD. This represents a pioneering step in translating the use of apoptotic cells to clinical practice for BMT, and possibly for other cell or solid organ transplantation.
CONSEQUENCES OF INFECTIONS ON TRANSPLANTATION TOLERANCE BY DONOR APOPTOTIC CELLS
Although induction of donor-specific tolerance by apoptotic cells in immunologically quiescent hosts promotes long-term graft function, opportunistic infections may negatively affect tolerance induction and/or its stability by enhancing host alloreactivity, and ultimately compromise graft function [39] . In this section, we will discuss how microbial infections may affect the efficacy of tolerance by apoptotic cells, and reciprocally how tolerance by apoptotic cells may affect antimicrobial immunity and viral latency activation.
Effects of acute infections on tolerance induction and maintenance
Cytomegalovirus (CMV) is a highly prevalent and clinically relevant pathogen in transplantation [40] . However, its impact on transplantation tolerance is not well defined. Employing murine CMV (MCMV) and an allogeneic islet transplantation model, we have recently reported that acute MCMV infection abrogates transplantation tolerance induction by donor ECDI-SP [41 && ]. This tolerance impairment correlates with an alteration in the differentiation and function of myeloid-derived suppressor cells (MDSCs), a heterogeneous population of immature myeloid cells implicated in transplantation tolerance [42] . Our study reveals that acute MCMV infection depresses the number of the highly immunosuppressive Gr1
HI granulocytic-MDSCs, whereas promotes the loss of MDSC-like suppressive function of the accumulating Ly6C
HI -monocytic cells and supports their gain of an immunostimulatory phenotype that now enhances T-cell alloreactivity. Consequently, the islet allograft exhibits an altered effector to regulatory T-cell ratio, which correlates with the ultimate graft demise (Fig. 1a) . Previously, it has been demonstrated that type 1 interferon signaling negatively affects tolerance induction during bacterial infection [43] . Supporting a role of type 1 interferon in mediating tolerance impairment in our model, we found that blocking type 1 interferon signaling during MCMV infection rescues MDSCs and restores transplantation tolerance [41 && ]. Although these data highlight that acute microbial infections may be a potential obstacle in the induction of transplantation tolerance employing donor apoptotic cells, an equally important question is how such infections may affect the maintenance of tolerance once it is established. Using Listeria monocytogenes infection in an anti-CD154 antibody (MR1) with DST allogeneic heart transplant tolerance model, Young et al. [44 && ] report that following an L. monocytogenes infection, majority of transplant recipients with established tolerance in fact experience an episode of rejection. They further demonstrate that though $60% of such recipients are able to recover partial graft function once L. monocytogenes infection has abated, tolerance-associated gene signature is nevertheless significantly altered, showing an 'erosion' of the previously established tolerance [44 && ]. Similarly, in a murine allogeneic islet transplantation model, we found that acute MCMV infection in previously tolerized recipients results into loss of islet allograft to acute rejection in $50% recipients (Dangi et al.; unpublished data). These data underscore the need for seeking effective therapies for maintaining and/or restoring full transplantation tolerance in settings of inadvertent microbial infections. The roles of type 1 interferon and MDSCs in this process provide potential targets for successful interventions.
Reciprocal effects between latent cytomegalovirus reactivation and transplantation tolerance
CMV reactivation from latency is common in transplant recipients because of transplant-induced inflammatory cytokines (e.g. IL-1b, IL-6, and TNFa), which initiate viral early gene expression [45] and chronic immunosuppression, which impairs anti-CMV immunity and facilitates viral replication [46] [47] [48] . Latent CMV reactivation has long been associated with graft dysfunction [40] . Transplantation tolerance can both minimize alloimmunityinduced inflammation and eliminate the need for chronic immunosuppression [36, 37] , therefore can theoretically prevent CMV reactivation from latency. We examined this hypothesis in our donor apoptotic ECDI-SP tolerance model of allogeneic kidney transplantation. In clinical kidney transplantation, CMV seronegative recipients (RÀ) receiving a kidney allograft from seropositive donors (Dþ) are at the highest risk for CMV reactivation [49] . Creating an experimental setting using seropositive donors to seronegative recipients (Dþ/ RÀ) in a mouse allogeneic kidney transplantation model, we observe that transplantation tolerance induced by donor apoptotic ECDI-SP is able to effectively prevent CMV reactivation by both inhibiting alloimmunity-induced inflammation and at the same time preserving host anti-CMV immunity (Dangi et al., manuscript in preparation). In contrast, in recipients chronically treated with immunosuppression, viral reactivation and dissemination from the latently infected kidney allograft are readily observed, together with a profoundly impaired host anti-CMV immunity. Therefore, our data support the notion that donor apoptotic cells as a relatively simple but robust strategy for tolerance induction can indeed prevent CMV reactivation and dissemination while preserving long-term graft survival.
On the other hand, CMV reactivation from latency is common when more aggressive regimens for tolerance induction, namely conditioning regimens in preparation for donor BMT, are used; and in some cases, lead to failure of tolerance itself. Currently, clinical experimental protocols for transplantation tolerance require BMT and chimerism induction [36, 37] . In a recent study using a BMTbased tolerance protocol in Cynomolgus macaques, CMV reactivation was reported in five out of eight recipients, all of whom experienced a subsequent loss of chimerism and tolerance [50 & ]. The authors conclude that early CMV reactivation and possibly anti-CMV therapy (ganciclovir and foscarnet) impair bone marrow engraftment, and therefore are major impediments to inducing chimerism and tolerance [50 & ]. Employing a protocol combining low-dose irradiation and costimulation-blockade in Rhesus macaques, Zheng et al. also report that sustained chimerism and tolerance can be readily achieved. However, this protocol was also accompanied by a significant risk for CMV reactivation and end-organ CMV diseases because of impaired host anti-CMV immunity [51 & ]. Therefore, these data suggest that aggressive conditioning protocols needed for BMT and chimerism for tolerance induction frequently promote CMV reactivation and may in fact hinder the establishment of transplantation tolerance. Alternatively, apoptotic cell-based tolerance protocols may be a more attractive approach as they do not require recipient bone marrow ablation, therefore minimize risks for CMV reactivation and its associated complications.
CONSEQUENCES OF PRIOR SENSITIZATION ON TRANSPLANTATION TOLERANCE BY DONOR APOPTOTIC CELLS
In addition to infections, another prominent factor known to modulate the outcome of tolerance attempts is preexisting alloreactive T-cell and B-cell memories generated during previous blood transfusions, prior transplantations, and pregnancies [52] . Owing to a low-activation threshold, memory cells mount quicker and more vigorous immune responses compared with their naïve counterparts. Therefore, sensitized recipients are highly challenging to transplant because of a high risk for accelerated graft rejection from memory immune responses [53, 54] . It has been shown that preexisting donor-specific antibodies (DSAs) in sensitized recipients can readily bind to graft endothelium and induce graft destruction by complement activation [55] . Thus, presence of DSAs may also pose a major barrier in inducing transplantation tolerance. In this context, using a DST transplantation tolerance model, Burns and Chong [56] demonstrate that preexisting DSAs opsonize the transfused donor cells, which in turn activate recipient APCs to stimulate, rather than inhibit, alloreactive T cells, and consequently accelerate allograft rejection. Using a rat islet transplant model, de Kort et al. [57] also demonstrate that pretransplant infusion of dexamethasone-treated donor dendritic cells intended for inducing tolerance in fact results in generation of alloreactive antibodies, which in turn precipitate accelerated islet allograft rejection.
DSAs have similarly been associated with loss of islet graft function in sensitized human islet transplant recipients [58] , although recent data suggest that if at low levels, they may be well tolerated without a consequence on the transplanted islets [59, 60] . In a sensitized murine model of allogeneic islet transplantation, we have observed that infusion of donor ECDI-SP indeed results in an accelerated loss of islets in comparison with unsensitized recipients, similar to that observed by Burns and de Kort (Dangi et al., manuscript in preparation). However, when additionally combined with a short course of rapamycin and MR1, ECDI-SP in fact significantly prolong islet allograft survival beyond that seen with rapamycin and MR1 alone. In our model, low level DSAs are comparable in both groups and do not correlate with graft outcome. These data suggest that for allogeneic islet transplantation in sensitized recipients with low levels of DSAs, cellular alloimmune memory responses may be a more critical factor for determining graft outcomes but are readily modifiable by donor apoptotic cells. Indeed, we observe that ECDI-SP, in combination with rapamycin and MR1, efficiently regulate alloimmune memory T-cell and B-cell responses in sensitized recipients (Dangi et al., manuscript in preparation). Thus, donor apoptotic cells can be combined with additional targeting strategies to control alloimmune memory responses in sensitized recipients, and therefore also have a promising role in promoting tolerance even in such recipients (Fig. 1b) .
CONCLUSION
Apoptotic cells exert profound immunosuppressive effects and promote immune homoeostasis and tolerance. Employing this strategy in various transplant models, several laboratories have demonstrated that robust transplantation tolerance and prolonged graft survival can be achieved. Recent data highlight that CMV infection and previous allosensitization constitute major obstacles for tolerance induction by this approach. These studies now form the basis for further investigations seeking effective strategies for promoting transplantation tolerance in such settings. Encouragingly, a recent clinical trial employing donor apoptotic cells in bone marrow transplantation has highlighted the safety of this approach and its efficacy in reducing GVHD, underscoring its clinical applicability and potentials for organ transplantation tolerance. This study demonstrated that in nonhuman primates, a prolonged mixed chimerism can be achieved to promote transplantation using a lengthy condition regimen but it is associated with a significant risk of CMV reactivation in these recipients. 
